Horizon Therapeutics PLC (HZNP): Price and Financial Metrics
GET POWR RATINGS... FREE!
HZNP POWR Grades
- HZNP scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.43% of US stocks.
- The strongest trend for HZNP is in Value, which has been heading down over the past 155 days.
- HZNP's current lowest rank is in the Stability metric (where it is better than 36.37% of US stocks).
HZNP Stock Summary
- HORIZON THERAPEUTICS PUBLIC LTD CO's market capitalization of $24,791,179,564 is ahead of 91.47% of US-listed equities.
- HZNP's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 387.35 -- higher than 92.36% of US-listed equities with positive expected earnings growth.
- With a price/earnings ratio of 47.54, HORIZON THERAPEUTICS PUBLIC LTD CO P/E ratio is greater than that of about 88.01% of stocks in our set with positive earnings.
- If you're looking for stocks that are quantitatively similar to HORIZON THERAPEUTICS PUBLIC LTD CO, a group of peers worth examining would be PAYC, HOLX, TECH, A, and RMD.
- Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Valuation Summary
- HZNP's price/earnings ratio is 47.5; this is 104.74% higher than that of the median Healthcare stock.
- Over the past 142 months, HZNP's EV/EBIT ratio has gone up 46.
Below are key valuation metrics over time for HZNP.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HZNP | 2023-03-24 | 6.8 | 4.9 | 47.5 | 40.9 |
| HZNP | 2023-03-23 | 6.8 | 4.9 | 47.2 | 40.7 |
| HZNP | 2023-03-22 | 6.8 | 4.8 | 47.0 | 40.5 |
| HZNP | 2023-03-21 | 6.9 | 4.9 | 47.9 | 41.2 |
| HZNP | 2023-03-20 | 6.8 | 4.9 | 47.6 | 41.0 |
| HZNP | 2023-03-17 | 6.9 | 4.9 | 47.8 | 41.1 |
HZNP Growth Metrics
- Its 2 year price growth rate is now at 124.58%.
- Its 4 year revenue growth rate is now at 37.93%.
- Its 3 year net cashflow from operations growth rate is now at 302.79%.
The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 3,629.044 | 1,257.842 | 521.482 |
| 2022-09-30 | 3,701.479 | 1,370.008 | 574.256 |
| 2022-06-30 | 3,813.112 | 1,414.584 | 764.96 |
| 2022-03-31 | 3,769.249 | 1,254.79 | 862.103 |
| 2021-12-31 | 3,226.41 | 1,035.271 | 534.491 |
| 2021-09-30 | 2,957.26 | 906.531 | 551.866 |
HZNP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HZNP has a Quality Grade of C, ranking ahead of 61.77% of graded US stocks.
- HZNP's asset turnover comes in at 0.385 -- ranking 123rd of 681 Pharmaceutical Products stocks.
- VNDA, NEOG, and CEMI are the stocks whose asset turnover ratios are most correlated with HZNP.
The table below shows HZNP's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.385 | 0.758 | 0.134 |
| 2021-06-30 | 0.367 | 0.759 | 0.130 |
| 2021-03-31 | 0.361 | 0.755 | 0.125 |
| 2020-12-31 | 0.425 | 0.758 | 0.237 |
| 2020-09-30 | 0.382 | 0.744 | 0.142 |
| 2020-06-30 | 0.357 | 0.734 | 0.038 |
HZNP Price Target
For more insight on analysts targets of HZNP, see our HZNP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $132.84 | Average Broker Recommendation | 1.33 (Strong Buy) |
HZNP Stock Price Chart Interactive Chart >
HZNP Price/Volume Stats
| Current price | $109.18 | 52-week high | $117.49 |
| Prev. close | $109.24 | 52-week low | $57.84 |
| Day low | $109.03 | Volume | 99,939 |
| Day high | $109.49 | Avg. volume | 2,385,035 |
| 50-day MA | $109.90 | Dividend yield | N/A |
| 200-day MA | $87.33 | Market Cap | 24.94B |
Horizon Therapeutics PLC (HZNP) Company Bio
Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019, shareholders of the company approved the change of the company's name to Horizon Therapeutics plc. (Source:Wikipedia)
Latest HZNP News From Around the Web
Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Should You Invest in Horizon Therapeutics Public Limited Company (HZNP)?Renaissance Investment Management, an investment management company, released its “Midcap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 11.23% (net) compared to a 6.90% return for the Russell Midcap Growth Index. The strategy declined -13.42% (net) in 2022 compared to a -26.72% decline […] |
Here's Why Horizon Therapeutics (HZNP) is a Strong Growth StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)DUBLIN, March 16, 2023--Horizon Therapeutics plc (NASDAQ: HZNP): |
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)DUBLIN, March 14, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (NANOS) March 11-16, 2023, in Orlando, Florida. |
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)DUBLIN, March 12, 2023--Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023. |
HZNP Price Returns
| 1-mo | -1.05% |
| 3-mo | -4.06% |
| 6-mo | 76.41% |
| 1-year | 3.77% |
| 3-year | 268.60% |
| 5-year | 668.87% |
| YTD | -4.06% |
| 2022 | 5.61% |
| 2021 | 47.31% |
| 2020 | 102.07% |
| 2019 | 85.26% |
| 2018 | 33.84% |
Continue Researching HZNP
Want to do more research on Horizon Therapeutics Public Ltd Co's stock and its price? Try the links below:Horizon Therapeutics Public Ltd Co (HZNP) Stock Price | Nasdaq
Horizon Therapeutics Public Ltd Co (HZNP) Stock Quote, History and News - Yahoo Finance
Horizon Therapeutics Public Ltd Co (HZNP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...